TY - JOUR AU - Ng, M. AU - Fleming, T. AU - Robinson, M. AU - Thomson, B. AU - Graetz, N. AU - Margono, C. AU - Mullany, E. C. AU - Biryukov, S. AU - Abbafati, C. AU - Abera, S. F. AU - Abraham, J. P. AU - Abu-Rmeileh, N. M. AU - Achoki, T. AU - AlBuhairan, F. S. AU - Alemu, Z. A. AU - Alfonso, R. AU - Ali, M. K. AU - Ali, R. AU - Guzman, N. A. AU - Ammar, W. AU - Anwari, P. AU - Banerjee, A. AU - Barquera, S. AU - Basu, S. AU - Bennett, D. A. AU - Bhutta, Z. AU - Blore, J. AU - Cabral, N. AU - Nonato, I. C. AU - Chang, J. C. PY - 2014 DA - 2014// TI - Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60460-8 DO - 10.1016/S0140-6736(14)60460-8 ID - Ng2014 ER - TY - JOUR AU - Hossain, P. AU - Kawar, B. AU - El Nahas, M. PY - 2007 DA - 2007// TI - Obesity and diabetes in the developing world-a growing challenge JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMp068177 DO - 10.1056/NEJMp068177 ID - Hossain2007 ER - TY - JOUR AU - Chan, J. C. AU - Malik, V. AU - Jia, W. AU - Kadowaki, T. AU - Yajnik, C. S. AU - Yoon, K. H. AU - Hu, F. B. PY - 2009 DA - 2009// TI - Diabetes in Asia: epidemiology, risk factors, and pathophysiology JO - JAMA VL - 301 UR - https://doi.org/10.1001/jama.2009.726 DO - 10.1001/jama.2009.726 ID - Chan2009 ER - TY - JOUR AU - Matsuzawa, Y. AU - Funahashi, T. AU - Kihara, S. AU - Shimomura, I. PY - 2004 DA - 2004// TI - Adiponectin and metabolic syndrome JO - Arterioscler Thromb Vasc Biol VL - 24 UR - https://doi.org/10.1161/01.ATV.0000099786.99623.EF DO - 10.1161/01.ATV.0000099786.99623.EF ID - Matsuzawa2004 ER - TY - JOUR AU - Holst, J. J. AU - Orskov, C. PY - 2004 DA - 2004// TI - The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism JO - Diabetes VL - 53 UR - https://doi.org/10.2337/diabetes.53.suppl_3.S197 DO - 10.2337/diabetes.53.suppl_3.S197 ID - Holst2004 ER - TY - JOUR AU - Abu-Hamdah, R. AU - Rabiee, A. AU - Meneilly, G. S. AU - Shannon, R. P. AU - Andersen, D. K. AU - Elahi, D. PY - 2009 DA - 2009// TI - Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides JO - J Clin Endocrinol Metab VL - 94 UR - https://doi.org/10.1210/jc.2008-1296 DO - 10.1210/jc.2008-1296 ID - Abu-Hamdah2009 ER - TY - JOUR AU - Agersø, H. AU - Jensen, L. B. AU - Elbrønd, B. AU - Rolan, P. AU - Zdravkovic, M. PY - 2002 DA - 2002// TI - The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men JO - Diabetologia VL - 45 UR - https://doi.org/10.1007/s00125-001-0719-z DO - 10.1007/s00125-001-0719-z ID - Agersø2002 ER - TY - JOUR AU - Garber, A. AU - Henry, R. R. AU - Ratner, R. AU - Hale, P. AU - Chang, C. T. AU - Bode, B. PY - 2011 DA - 2011// TI - Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes JO - Diabetes Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2010.01356.x DO - 10.1111/j.1463-1326.2010.01356.x ID - Garber2011 ER - TY - JOUR AU - Nauck, M. AU - Frid, A. AU - Hermansen, K. AU - Thomsen, A. B. AU - During, M. AU - Shah, N. AU - Tankova, T. AU - Mitha, I. AU - Matthews, D. R. PY - 2013 DA - 2013// TI - Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study JO - Diabetes Obes Metab VL - 15 UR - https://doi.org/10.1111/dom.12012 DO - 10.1111/dom.12012 ID - Nauck2013 ER - TY - JOUR AU - Inoue, K. AU - Maeda, N. AU - Kashine, S. AU - Fujishima, Y. AU - Kozawa, J. AU - Hiuge-Shimizu, A. AU - Okita, K. AU - Imagawa, A. AU - Funahashi, T. AU - Shimomura, I. PY - 2011 DA - 2011// TI - Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes JO - Cardiovasc Diabetol VL - 10 UR - https://doi.org/10.1186/1475-2840-10-109 DO - 10.1186/1475-2840-10-109 ID - Inoue2011 ER - TY - JOUR AU - Fujishima, Y. AU - Maeda, N. AU - Inoue, K. AU - Kashine, S. AU - Nishizawa, H. AU - Hirata, A. AU - Kozawa, J. AU - Yasuda, T. AU - Okita, K. AU - Imagawa, A. AU - Funahashi, T. AU - Shimomura, I. PY - 2012 DA - 2012// TI - Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes JO - Cardiovasc Diabetol VL - 11 UR - https://doi.org/10.1186/1475-2840-11-107 DO - 10.1186/1475-2840-11-107 ID - Fujishima2012 ER - TY - JOUR AU - Raun, K. AU - von Voss, P. AU - Gotfredsen, C. F. AU - Golozoubova, V. AU - Rolin, B. AU - Knudsen, L. B. PY - 2007 DA - 2007// TI - Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not JO - Diabetes VL - 56 UR - https://doi.org/10.2337/db06-0565 DO - 10.2337/db06-0565 ID - Raun2007 ER - TY - JOUR AU - Raun, K. AU - von Voss, P. AU - Knudsen, L. B. PY - 2007 DA - 2007// TI - Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs JO - Obesity (Silver Spring) VL - 15 UR - https://doi.org/10.1038/oby.2007.204 DO - 10.1038/oby.2007.204 ID - Raun2007 ER - TY - JOUR AU - Hunter, K. AU - Hölscher, C. PY - 2012 DA - 2012// TI - Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis JO - BMC Neurosci VL - 13 UR - https://doi.org/10.1186/1471-2202-13-33 DO - 10.1186/1471-2202-13-33 ID - Hunter2012 ER - TY - JOUR AU - Ussher, J. R. AU - Drucker, D. J. PY - 2014 DA - 2014// TI - Cardiovascular actions of incretin-based therapies JO - Circ Res VL - 114 UR - https://doi.org/10.1161/CIRCRESAHA.114.301958 DO - 10.1161/CIRCRESAHA.114.301958 ID - Ussher2014 ER - TY - JOUR AU - Horowitz, M. AU - Flint, A. AU - Jones, K. L. AU - Hindsberger, C. AU - Rasmussen, M. F. AU - Kapitza, C. AU - Doran, S. AU - Jax, T. AU - Zdravkovic, M. AU - Chapman, I. M. PY - 2012 DA - 2012// TI - Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes JO - Diabetes Res Clin Pract VL - 97 UR - https://doi.org/10.1016/j.diabres.2012.02.016 DO - 10.1016/j.diabres.2012.02.016 ID - Horowitz2012 ER - TY - JOUR AU - Fadini, G. P. AU - Simioni, N. AU - Frison, V. AU - Dal Pos, M. AU - Bettio, M. AU - Rocchini, P. AU - Avogaro, A. PY - 2013 DA - 2013// TI - Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients JO - Acta Diabetol VL - 50 UR - https://doi.org/10.1007/s00592-013-0489-3 DO - 10.1007/s00592-013-0489-3 ID - Fadini2013 ER - TY - JOUR AU - Arakawa, M. AU - Mita, T. AU - Azuma, K. AU - Ebato, C. AU - Goto, H. AU - Nomiyama, T. AU - Fujitani, Y. AU - Hirose, T. AU - Kawamori, R. AU - Watada, H. PY - 2010 DA - 2010// TI - Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 JO - Diabetes VL - 59 UR - https://doi.org/10.2337/db09-1694 DO - 10.2337/db09-1694 ID - Arakawa2010 ER - TY - JOUR AU - Rizzo, M. AU - Chandalia, M. AU - Patti, A. M. AU - Di Bartolo, V. AU - Rizvi, A. A. AU - Montalto, G. AU - Abate, N. PY - 2014 DA - 2014// TI - Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study JO - Cardiovasc Diabetol VL - 13 UR - https://doi.org/10.1186/1475-2840-13-49 DO - 10.1186/1475-2840-13-49 ID - Rizzo2014 ER - TY - JOUR AU - Chilton, R. AU - Wyatt, J. AU - Nandish, S. AU - Oliveros, R. AU - Lujan, M. PY - 2011 DA - 2011// TI - Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon-like peptide-1-based therapies JO - Am J Med VL - 124 UR - https://doi.org/10.1016/j.amjmed.2010.11.004 DO - 10.1016/j.amjmed.2010.11.004 ID - Chilton2011 ER - TY - JOUR AU - Sivertsen, J. AU - Rosenmeier, J. AU - Holst, J. J. AU - Vilsbøll, T. PY - 2012 DA - 2012// TI - The effect of glucagon-like peptide 1 on cardiovascular risk JO - Nat Rev Cardiol VL - 9 UR - https://doi.org/10.1038/nrcardio.2011.211 DO - 10.1038/nrcardio.2011.211 ID - Sivertsen2012 ER - TY - JOUR AU - Drucker, D. J. PY - 2013 DA - 2013// TI - Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls JO - Diabetes VL - 62 UR - https://doi.org/10.2337/db13-0822 DO - 10.2337/db13-0822 ID - Drucker2013 ER - TY - JOUR AU - Wing, R. R. AU - Lang, W. AU - Wadden, T. A. AU - Safford, M. AU - Knowler, W. C. AU - Bertoni, A. G. AU - Hill, J. O. AU - Brancati, F. L. AU - Peters, A. AU - Wagenknecht, L. PY - 2011 DA - 2011// TI - Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes JO - Diabetes Care VL - 34 UR - https://doi.org/10.2337/dc10-2415 DO - 10.2337/dc10-2415 ID - Wing2011 ER - TY - JOUR AU - Klonoff, D. C. AU - Buse, J. B. AU - Nielsen, L. L. AU - Guan, X. AU - Bowlus, C. L. AU - Holcombe, J. H. AU - Wintle, M. E. AU - Maggs, D. G. PY - 2008 DA - 2008// TI - Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years JO - Curr Med Res Opin VL - 24 UR - https://doi.org/10.1185/030079907X253870 DO - 10.1185/030079907X253870 ID - Klonoff2008 ER -